Brian M. Culley - 11 Feb 2026 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
President and CEO, Director
Signature
/s/ Brian M. Culley
Issuer symbol
LCTX
Transactions as of
11 Feb 2026
Net transactions value
-$23,164
Form type
4
Filing time
13 Feb 2026, 19:30:06 UTC
Previous filing
19 Dec 2025
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Culley Brian M President and CEO, Director C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD /s/ Brian M. Culley 13 Feb 2026 0001310683

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares Options Exercise +31,250 +14% 253,385 11 Feb 2026 Direct F1, F2
transaction LCTX Common Shares Tax liability $23,164 -12,869 -5.1% $1.80 240,516 11 Feb 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Options Exercise $0 -31,250 -100% $0.000000 0 11 Feb 2026 Common Shares 31,250 $0.000000 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,250 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
F4 The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.